Hormone therapy and its risk after gynecological malignancy operation / 中国实用妇科与产科杂志
Chinese Journal of Practical Gynecology and Obstetrics
;
(12): 651-654, 2019.
Artigo
em Chinês
| WPRIM
| ID: wpr-816231
ABSTRACT
With the improvement of therapy,the survival time of patients with gynecological malignant tumor is prolonged,so improving their quality of life has become a new challenge for doctors.These patients may be in perimenopause themselves,or be in artificial menopause due to tumor treatment,and their climacteric symptoms are more obvious than those in natural menopause.Whether hormone therapy could be used to relieve the climacteric symptoms in these patients is still controversial at present.Clinicians should give individualized hormone therapy cautiously on the basis of patients' informed consent.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Estudo de etiologia
Idioma:
Chinês
Revista:
Chinese Journal of Practical Gynecology and Obstetrics
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS